Neurotensin agonists: Potential in the treatment of schizophrenia

Mona Boules, Amanda Shaw, Paul Fredrickson, Elliott Richelson

Research output: Contribution to journalReview articlepeer-review

43 Scopus citations


Neurotensin (NT) is a neuropeptide that, for decades, has been implicated in the biology of schizophrenia. It is closely associated with, and is thought to modulate, dopaminergic and other neurotransmitter systems involved in the pathophysiology of various neuropsychiatric diseases, including schizophrenia. This review outlines the neurochemistry and function of the NT system and the data implicating its role in schizophrenia. The data suggest that NT receptor agonists have the potential to be used as novel therapeutic agents for the treatment of schizophrenia, with the added benefits of (i) not causing weight gain, an adverse effect that is problematic with some of the currently used atypical antipsychotic drugs; and (ii) helping patients to stop smoking, a behaviour that is highly prevalent in those with schizophrenia.

Original languageEnglish (US)
Pages (from-to)13-23
Number of pages11
JournalCNS Drugs
Issue number1
StatePublished - 2007

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Neurotensin agonists: Potential in the treatment of schizophrenia'. Together they form a unique fingerprint.

Cite this